Clinical Scorecard: Effective Weight Management in Overweight or Obese Adolescents Through the Use of a Swallowable Intragastric Balloon and Dietary Guidance

At a Glance

Key Highlights

• Obesity in adolescents is a chronic disease linked to multiple comorbidities and reduced life expectancy.
• Swallowable intragastric balloon (SGB) placement is a minimally invasive, anesthesia-free outpatient procedure.
• SGB combined with a digital app and connected scale supports weight loss and lifestyle modification over approximately 4 months.

Guideline-Based Recommendations

Diagnosis

• Assess BMI and obesity-related comorbidities in adolescents.
• Evaluate previous non-response to behavioral and dietary interventions.

Management

• Consider SGB placement for adolescents with BMI ≥ 27 kg/m2 after multidisciplinary evaluation and parental consent.
• Implement dietary and lifestyle changes supported by digital tools alongside SGB therapy.
• Avoid bariatric surgery in adolescents unless BMI >35 kg/m2 with comorbidities or >40 kg/m2 without comorbidities, per expert guidelines.

Monitoring & Follow-up

• Follow-up via virtual system with connected scale and smartphone app to monitor weight and adherence.
• Monitor for procedure- and device-related adverse events during and after balloon placement.

Risks

• Contraindications include difficulty swallowing, risk of bowel obstruction, gastric perforation, GI bleeding, psychiatric illness, eating disorders, pancreatitis, and significant respiratory disease.
• Potential adverse events related to balloon placement and passage must be disclosed and monitored.

Patient & Prescribing Data

Adolescents aged 15-17 years with overweight or obesity unresponsive to prior behavioral and dietary interventions

SGB placement is feasible without anesthesia or endoscopy, with natural balloon passage after ~4 months; combined digital support enhances engagement and weight loss outcomes.

Clinical Best Practices

• Ensure comprehensive education and informed consent including discussion of off-label use and potential risks.
• Perform multidisciplinary evaluation including assessment of puberty status and comorbidities prior to SGB placement.
• Use virtual follow-up tools to maintain patient engagement and monitor progress remotely.
• Adhere to exclusion criteria to minimize risk of adverse events.
• Provide parental/guardian involvement and support throughout treatment.

References

• World Health Organization Global Strategy on Diet, Physical Activity and Health
• International Pediatric Endosurgery Group (IPEG) Guidelines on Bariatric Procedures in Children
• Allurion Technologies - Swallowable Gastric Balloon